Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Quinolinone derivatives
US9855260B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9855260-B2 |
| Application number | US-201514708424-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 11, 2015 |
| Priority date | Mar 7, 2011 |
| Publication date | Jan 2, 2018 |
| Grant date | Jan 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds of the formula (I), salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds as activators of AMPK.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a disease selected from the group consisting of type 2 diabetes and metabolic syndrome, which method comprises administering to a subject in need thereof a therapeutically effective amount of a compound which is 7-chloro-6-(4-(dimethylamino)phenyl)-4-hydroxy-3-(3-methylisoxazol-5-yl)quinolin-2(1H)-one, represented by the formula: or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1 wherein the compound is 7-chloro-6-(4-(dimethylamino)phenyl)-4-hydroxy-3-(3-methylisoxazol-5-yl)quinolin-2(1H)-one, represented by the formula: 3. The method according to claim 1 wherein the disease is type 2 diabetes. 4. The method according to claim 2 wherein the disease is type 2 diabetes. 5. The method according to claim 1 wherein the disease is metabolic syndrome. 6. The method according to claim 2 wherein the disease is metabolic syndrome.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antihyperlipidemics · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antineoplastic agents · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9855260B2 cover?
- The present invention relates to compounds of the formula (I), salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds as activators of AMPK.
- Who is the assignee on this patent?
- Glaxosmithkline Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).